lab technician performs quality control tests capsules

A lab technician performs quality control tests on capsules of DREPAF, a generic formulation used to treat sickle cell disease, at a Teranga Pharma laboratory in Mbao, on July 27, 2026. The lab is producing generic hydroxyurea, the gold standard in sickle cell treatment, for the first time ever in Africa. Africa accounts for nearly 80 percent of all sickle cell disease cases. Yet the continent remains largely dependent on expensive treatments imported from Europe and the Americas, especially hydroxyurea, the treatment recommended by the World Health Organization (WHO).The medication helps reduce painful crises, hospitalisations, the need for blood transfusions and death, according to the organisation.
SEYLLOU/AFP via Getty Images

Novo Nordisk submitted etavopivat, a once-daily pill for sickle cell disease, to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on Friday, asking regulators to approve it for people 12 and older. The filing rests on a phase 3 trial that cut painful vaso-occlusive crises 27% (VOCs) versus placebo.

The filing matters to 100,000 Americans and 110,000 Europeans living with the disease, about 8 million people worldwide. Novo says the FDA and the European Commission are expected to act in 2027, but its announcement does not say whether either agency has accepted the applications or set review dates.

The detail that separates this filing from the field is the evidence behind it. Two earlier sickle cell drugs left European or global markets after safety and efficacy data fell short, and the FDA extended its mitapivat review of a rival pill over a safety question. Etavopivat arrives with a crisis reduction alongside a hemoglobin gain, both co-primary endpoints in its phase 3 trial. Novo has not yet published the full dataset and says detailed results will come at a future scientific conference.

Etavopivat is a selective activator of pyruvate kinase in red blood cells (PKR). Novo acquired it in 2022 in its $1.1 billion purchase of Forma Therapeutics. The FDA has granted it Fast Track, Rare Pediatric Disease and Orphan Drug designations, and the European Commission has granted Orphan Drug status after a positive opinion from the EMA’s orphan medicines committee.

How Does Etavopivat Work Against Sickle Cell Disease?

Sickle cell disease is driven by sickle hemoglobin that clumps into polymers inside red blood cells, producing hemolytic anemia and VOCs. Sickled cells survive roughly 10 to 20 days, compared with 90 to 120 days for healthy cells.

Red blood cells have no mitochondria and rely on anaerobic glycolysis for energy, and PKR is an enzyme in that pathway. According to Novo, activating PKR lowers levels of a molecule called 2,3-diphosphoglycerate (2,3-DPG) and raises production of the energy carrier adenosine triphosphate (ATP). Lower 2,3-DPG increases hemoglobin’s affinity for oxygen, which is intended to prevent sickle hemoglobin from polymerizing. Higher ATP is meant to preserve the red cell membrane and its flexibility, extending cell survival.

Dosing is a practical difference within the class. Etavopivat is taken 400 mg once daily in the phase 3 trial. Mitapivat, the nearest rival PK activator, was tested in sickle cell disease at 100 mg twice daily.

HIBISCUS Phase 3 Cut Pain Crises 27% and Lifted Hemoglobin Response to 48.7%

The submission rests on HIBISCUS (NCT04624659), a phase 2/3 program of about 440 participants. A 60-patient phase 2 portion tested 200 mg and 400 mg doses against placebo, and the 400 mg dose moved forward. The phase 3 portion randomized 385 participants to etavopivat or placebo, with crisis rates measured at week 52.

Topline results announced in April showed the drug met both co-primary endpoints:

Crises: The annualized VOC rate fell 27% versus placebo. The median time to first VOC was 38.4 weeks on etavopivat versus 20.9 weeks on placebo, a gap of roughly four months.Hemoglobin: At week 24, 48.7% of etavopivat patients had a hemoglobin rise above 1 g/dL, versus 7.2% on placebo.Transfusions: Participants on etavopivat were significantly less likely to need transfusions in an exploratory analysis, though the announcements reviewed for this article gave no figures.

Martin Holst Lange, Novo Nordisk’s chief scientific officer, said the company is “hopeful that etavopivat can provide a new disease-modifying treatment option” if approved.

Oxbryta Withdrawal Put Hemoglobin Gains Under Scrutiny as Proof of Benefit

Pfizer pulled Oxbryta from all markets (voxelotor) in September 2024 after a review found an imbalance in vaso-occlusive crises and fatal events. Oxbryta won U.S. accelerated approval in 2019 on a hemoglobin increase above 1 g/dL after 24 weeks of dosing.

A hemoglobin response is a surrogate endpoint, a lab measure meant to stand in for how patients actually feel and function. Accelerated approval relies on surrogate endpoints and requires confirmatory trials with clinical endpoints. Novartis’s Adakveo (crizanlizumab) shows the other failure mode: the European Commission revoked its authorization in 2023 after the phase 3 STAND trial did not reduce painful crises leading to a health care visit.

That history is the context for etavopivat’s package. Novo’s own description of HIBISCUS lists hemoglobin response at week 24 and a reduction in annualized VOCs at week 52 as the measures under evaluation. Novo’s announcement does not say whether the FDA will review the application under accelerated or traditional approval.

Mitapivat Missed Pain-Crisis Endpoint and Faces REMS Question at FDA

Agios Pharmaceuticals’ mitapivat, another PK activator, is the nearest rival and is also under FDA review for sickle cell disease. In the RISE UP phase 3 trial of 207 patients aged 16 and older, 40.6% reached a hemoglobin response versus 2.9% on placebo, but the annualized pain-crisis rate of 2.62 versus 3.05 was not statistically significant (p=0.1213).

Agios sought accelerated approval, and the FDA granted priority review of a supplemental application submitted May 12. A confirmatory trial, REIGNITE, will measure whether mitapivat reduces transfusion burden. On October 9, the FDA requested more information to decide whether a risk evaluation and mitigation strategy (REMS) is needed, a program that can require lab testing and prescriber certification. After Agios submitted about nine months of updated safety data, the agency treated the response as a major amendment and moved its goal date from November 1 to February 1, 2027.

Mitapivat already carries a boxed warning and a REMS in thalassemia. The FDA approved it there in December 2025 after five patients in two phase 3 trials had reactions suggestive of hepatocellular injury, two of whom were hospitalized. Agios reported no similar liver injury in sickle cell patients, a company statement this article could not independently confirm.

Analysts see the competitive pressure. After Agios discontinued its second sickle cell candidate, tebapivat, in July, Truist analyst Gregory Renza said the move increases reliance on mitapivat as “the bar for differentiation” rises after etavopivat’s late-stage results.

Cross-trial comparisons are unreliable. HIBISCUS enrolled people 12 and older and RISE UP enrolled people 16 and older, the designs and populations differ, and etavopivat’s full dataset is not public.

Does Etavopivat Carry Liver Risk, and What Data Remain Unpublished?

Novo says etavopivat was well tolerated, with a safety profile similar to earlier trials, but published coverage of the results includes no adverse-event rates. Detailed results will be presented at a future scientific conference and published in a peer-reviewed journal.

The earlier data offer limited guidance. In the 60-patient phase 2 portion, two serious adverse events were judged possibly drug-related: elevated hepatic enzymes in one patient on the 200 mg dose, and decreased hemoglobin in one patient on the 400 mg dose that advanced to phase 3. That phase 2 portion also missed statistical significance on its crisis-rate analysis of all randomized patients (p=0.154), though a per-protocol analysis reached significance (p=0.020 at 200 mg and p=0.028 at 400 mg).

Long-term safety data will come from FLORAL, an open-label extension, while a second phase 3 study, HIBISCUS 2 (NCT06612268), expects to enroll about 510 people.

Regulators Have Not Confirmed Acceptance of Filings, With Decisions Expected in 2027

Congress revived the FDA’s rare pediatric disease priority review voucher program on February 3, 2026, authorizing designations through September 2029. Vouchers are transferable and sell for over $100 million. Etavopivat carries a Rare Pediatric Disease designation, and Novo’s announcement does not say whether it will seek a voucher.

For patients and clinicians, three markers will show how etavopivat’s evidence holds up: the full HIBISCUS safety and liver data, the February 1, 2027 decision on mitapivat as a possible signal of how the agency weighs hemoglobin gains and REMS requirements, and whether regulators accept Novo’s filing and say which approval pathway applies. Most people with sickle cell disease live in low- and middle-income countries, where access to any new therapy remains a separate challenge.

Frequently Asked QuestionsWhen could etavopivat be approved?

Novo says the FDA is expected to act on its New Drug Application in 2027, and the European Commission is expected to act on the Marketing Authorization Application in 2027. The company did not say whether either agency has accepted the filings.

How is etavopivat different from mitapivat?

Both are oral PK activators, but etavopivat is taken once daily, while mitapivat was tested at 100 mg twice daily. In their phase 3 trials, etavopivat met its crisis endpoint and mitapivat did not reach significance on crises, though the studies differ in age range and design, so the results cannot be compared directly.

Why does Oxbryta’s withdrawal matter for new sickle cell pills?

Oxbryta raised hemoglobin, but Pfizer withdrew it worldwide in 2024 after data showed an imbalance in crises and fatal events, so regulators and clinicians have reason to look beyond hemoglobin alone. An analysis of mitapivat’s trial asked whether a hemoglobin response without a significant pain-crisis reduction justifies calling a drug disease-modifying.

Who could take etavopivat if it is approved?

Novo is seeking approval for adolescents and adults aged 12 and older with sickle cell disease. Orphan Drug status in the United States carries seven years of market exclusivity, and in the European Union it carries 10 years.